NCT03949530View on ClinicalTrials.gov

A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 16, 2019

Primary Completion Date

March 29, 2020

Study Completion Date

March 29, 2020

Conditions
Healthy VolunteersIdiopathic Pulmonary Fibrosis
Interventions
DRUG

IDL-2965 Oral Capsule

Investigational drug

DRUG

Placebos

Placebo

Trial Locations (1)

Unknown

Covance CRU, Leeds

Sponsors
All Listed Sponsors
lead

Indalo Therapeutics, Inc.

INDUSTRY